Shots:

• The companies jointly enter into P-I trial evaluating the clinical benefits- combining immune stimulator- Immuntep’s eftilagimod alpha (“efti” or “IMP321”)- with Merck and Pfizer’s avelumab. Alliances will jointly develop and commercialize avelumab
• The Institute of Clinical Cancer Research- will sponsor the trial- conducted & involved under ongoing INSIGHT clinical study evaluating P-II dose of efti when combined with avelumab in patients with advanced solid malignancies- assessing its safety- efficacy and tolerability
• Avelumab is a human anti-programmed death ligand-1 (PD-L1) Ab currently being evaluated in JAVELIN clinical development program with seven P-III trials. Eftilagimod is a LAG-3Ig fusion protein currently in P-IIb chemoimmunotherapy for metastatic breast cancer and in P-I combination therapy trial for metastatic melanoma termed TACTI-mel

Ref: Immuntep | Image:  Wikimedia